ARF5 and neoplasm: Strikingly, IQSEC1, ARF5 and ARF6 increase similarly stratified patient survival when all tumour types were considered together, providing an exceptional >9-year (111 months) median survival increase for non-IQSEC1-ARF5/6-amplified patients (across 9307 patients) (Fig. 8p).